| Identification | Back Directory | [Name]
ALPHA-BOSWELLIC ACID | [CAS]
471-66-9 | [Synonyms]
α-BoswellicAci
α-Boswellic acid
A-BOSWELLIC ACID
BOSWELLIC ACID, A-
ALPHA-BOSWELLIC ACID
A-ALPHA-BOSWELLIC ACID
BOSWELLIC ACID, a-(SH)
boswellic acid extract
Boswelia Serrata extract
alpha-Boswellic acid, >98%
Boswellic Acid,a-Boswellic Acid
3α-hydroxyolean-12-en-24-oic Acid
3alpha-Hydroxy-12-oleanen-24-oic acid
Boswellin Extract/beta-boswellic acid
(4R)-3α-Hydroxyolean-12-en-24-oic acid
alpha-Boswellic acid (α-Boswellic acid)
(3α,4β)-3-Hydroxyolean-12-en-23-oic Acid
(3alpha)-3-hydroxyolean-12-en-24-oic acid
(18β)-3α-Hydroxygermanica-12-ene-24-oic acid
Olean-12-en-23-oicacid, 3-hydroxy-, (3a,4b)-
Olean-12-en-23-oic acid, 3-hydroxy-, (3α,4β)-
α-Boswellic acid, 98%, from Boswellia carterii Birdw. | [Molecular Formula]
C30H48O3 | [MDL Number]
MFCD03788779 | [MOL File]
471-66-9.mol | [Molecular Weight]
456.7 |
| Chemical Properties | Back Directory | [Melting point ]
289℃ | [Boiling point ]
552.7±50.0 °C(Predicted) | [density ]
1.10±0.1 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Inert atmosphere,Room temperature | [solubility ]
Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
4.50±0.70(Predicted) | [color ]
White to Off-White | [Water Solubility ]
practically insoluble in water | [BRN ]
3074442 | [LogP]
9.430 (est) |
| Hazard Information | Back Directory | [Uses]
ALPHA-BOSWELLIC ACID is the principal constitutents of frankincense (olibanum). A specific, nonredox inhibitor of 5-lipoxygenase used to treat inflammation.
| [in vivo]
alpha-Boswellic acid (3 or 10 mg/kg, intraperitoneal injection) decreases epidermal thickening, mast cell count and dermal infiltration in BALB/c mice induced by 2, 4-dinitrochlorobenzene[1].
alpha-Boswellic acid (200 mg/kg, gavage) has a protective effect on ethanol-induced gastric injury in rats[2].
| Animal Model: | 2,4-Dinitrochlorobenzene-Induced Atopic-like Dermatitis in BALB/c Mice[1] | | Dosage: | 3 or 10 mg/kg | | Administration: | i.p. | | Result: | Reduced the severity of the AD-like symptoms.
Attenuated the increase in ear thickness and decreased cutaneous TEWL in DNCB-treated mice.
|
| Animal Model: | Ethanol-induced gastric injury in rats[2] | | Dosage: | 200 mg/kg | | Administration: | i.g. | | Result: | Reduced injuries associated with the administration of ethanol, gastric juice acidity and the formation of MDA and increased CAT activity and SOD activity and the level of NO and PGE-2 in a dose-depended manner.
Increased the expression of both Nrf2 and HO-1.
|
| [target]
NO | PGE | Nrf2 | HO-1 | ROS |
|
|